StockData
Hims & Hers Health, Inc. logo

Hims & Hers Health, Inc. (HIMS) KPIs and segments

HIMSNYSEServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/30171% above fair value
$17.05−0.50 (-2.85%)

Close on Nov 18, 2026Market cap $3.98BP/E –Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Hims & Hers Health · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Hims & Hers Health: 51 chỉ số vận hành, trong đó có Subscribers (End of Period), Net Orders (Legacy, Discontinued After Q4 2024) và Average Order Value, lấy từ 122 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
United States($M)
622530537579
Non-US($M)
13178.27.557.32
Subscribers (End of Period)3
2,788.002,891.002,584.002,511.002,471.002,439.002,366.002,229.002,047.001,864.001,709.001,537.00
Subscribers YoY Growth (Disclosed)(%)
13.0%19.0%9.0%13.0%21.0%31.0%38.0%45.0%44.0%43.0%41.0%48.0%
Personalized Subscribers (Legacy Slide Disclosure Through Q1 2026)(M)
1.701.601.601.501.401.2010.800.600.50
Non-Personalized Subscribers (Legacy Slide Disclosure Through Q1 2026)(M)
0.900.900.900.901111.101.101
Net Orders (Legacy, Discontinued After Q4 2024)1
2,807.002,664.002,527.002,461.002,298.00
Net Orders YoY Growth (Legacy, Disclosed Through Q4 2024)(%)
22.0%20.0%20.0%20.0%24.0%
Average Order Value — AOV (Legacy, Discontinued After Q4 2024)($)1
168147121109103
Average Order Value YoY Growth (Legacy, Disclosed Through Q4 2024)(%)
63.0%48.0%27.0%21.0%18.0%
Monthly Revenue per Average Subscriber($)3
105928083817685756859
Monthly Revenue per Average Subscriber YoY Growth (Disclosed)(%)
30.0%21.0%-6.0%11.0%
Monthly Online Revenue per Average Subscriber (Legacy, Discontinued After Q4 2025)($)
828074847367575553
Monthly Online Revenue per Average Subscriber YoY Growth (Legacy, Disclosed)(%)
12.0%19.0%30.0%53.0%38.0%24.0%8.0%
Online Revenue (Legacy Channel Split, Discontinued After Q4 2025)($M)1
609589537576471393307268237
Online Revenue YoY Growth (Legacy, Disclosed Through Q4 2025)(%)
29.0%50.0%75.0%115.0%98.0%79.0%53.0%45.0%47.0%
Wholesale Revenue (Legacy Channel Split, Discontinued After Q4 2025)($M)1
8.709.9089.6010.498.8010.49.30
Wholesale Revenue YoY Growth (Legacy, Disclosed Through Q4 2025)(%)
-16.0%10.0%-10.0%-7.0%12.0%28.0%31.0%58.0%53.0%
Consolidated Revenue YoY Growth (Disclosed)(%)2
49.0%38.0%4.0%28.0%49.0%73.0%111.0%95.0%77.0%52.0%46.0%47.0%
United States Revenue YoY Growth (Disclosed)(%)
21.0%16.0%-8.0%17.0%
Rest of the World Revenue YoY Growth (Disclosed)(%)
321.0%1,641.0%969.0%825.0%
Management Revenue Guidance — Low End($M)1
880680600605570530520465375292267243
Management Revenue Guidance — High End($M)
900700625625590550540470380297272248
Management Adjusted EBITDA Guidance — Low End($M)1
753535556065555035302214
Management Adjusted EBITDA Guidance — High End($M)
955555657075655540352717
Customer Acquisition Costs — Paid Media & Advertising Spend($M)
214230193206203188202197161124113
Marketing Expense (GAAP)($M)4
247262222238232218231221182145131126
Marketing Employee Compensation (ex-SBC)($M)
10.210.513.110.69.8011.510.59998.70
Marketing Stock-Based Compensation($M)
4.1032.803.203.103.402.802.602.502.401.901.60
Adjusted Marketing Expense (Non-GAAP)($M)
243259219
GAAP Marketing Expense as % of Revenue (Disclosed on Earnings Calls)(%)
28.0%34.0%36.0%39.0%39.0%
Operations and Support Expense (GAAP)($M)3
10795.596.580.176.866.56358.147.541.538.732.8
Operations & Support Employee Compensation (ex-SBC)($M)
36.335.435.732.330.826.523.82118.61716.6
Operations & Support Stock-Based Compensation($M)
10.976.105.905.504.6032.702.602.702.201.90
Adjusted Operations and Support Expense (Non-GAAP)($M)
92.583.885.4
Technology and Development Expense (GAAP)($M)4
69.454.946.94140.637.829.923.721.118.715.313.4
Technology & Development Employee Compensation (ex-SBC)($M)
14.615.318.417.61415.813.511.910.59.108
Technology & Development Stock-Based Compensation($M)
12.66.6065.104.805.2043.803.303.202.201.90
Capitalized Stock-Based Compensation (Website & Internal-Use Software)($M)
3.102.301.40110.900.700.500.500.700.600.40
Adjusted Technology and Development Expense (Non-GAAP)($M)
44.248.340.9
General & Administrative Employee Compensation (ex-SBC)($M)2
49.843.63021.31919.614.713.711.811.810.8
General & Administrative Stock-Based Compensation($M)
36.925.521.920.326.822.51515.116.515.812.812.4
Adjusted General and Administrative Expense (Non-GAAP)($M)
91.763.659.4
GAAP Gross Margin (Disclosed)(%)2
57.0%64.0%65.0%72.0%74.0%76.0%73.0%77.0%79.0%81.0%82.0%83.0%
Adjusted Gross Profit (Non-GAAP)($M)
509481425
Adjusted Gross Margin (Non-GAAP)(%)
57.0%64.0%70.0%
Adjusted EBITDA($M)2
82.460.344.366.378.482.291.154.151.139.332.320.6
Adjusted EBITDA Margin (Disclosed)(%)
9.0%8.0%7.0%11.0%13.0%15.0%16.0%11.0%13.0%12.0%12.0%8.0%
Adjusted Net Income (Loss) (Non-GAAP)($M)
6.50-20.8-43.6
Free Cash Flow (Non-GAAP)($M)
26-68.253-2.6079.4-69.450.159.579.447.611.910.8
U.S. Licensed Medical Providers (Affiliated Medical Groups)2
Medical Consultation & Pharmacy Services Charged by Affiliated VIEs($M)
28.126.928.475.995.496.612786.857.83933.124.8
Affiliated Medical Group & Pharmacy VIEs Net Income (Loss)($M)
-2.20-2.901.607.10-7-5.80-7.70-9.30-11.5-4.60-0.80-2.90
Property, Equipment and Software, Net($M)6
39136433431226720615682.152.149.545.236.1
Property, Equipment and Software, Gross($M)
47343539636531224218510772.166.759.548.4
Assets Not Yet Placed in Service — Pharmacy, Sterile & Peptide Buildout($M)
23924722321417311467.633.85.9015.513.114.9
Pharmacy & Fulfillment Facility Equipment, Gross($M)
11097.691.583.28075.771.527.824.612.911.78.30
Website Development & Internal-Use Software, Gross($M)
66.660.656.251.14640.934.834.131.329.526.423
Leasehold Improvements, Gross($M)
57.430.725.115.913.411.911.410.910.28.908.202.30
Accumulated Depreciation & Amortization on PP&E and Software($M)
81.471.261.852.644.636.629.724.519.917.114.212.2
Cash Capital Expenditures — Property, Equipment & Intangibles($M)1
33.325.929.859.465.346.155.324.53.303.2010.68.60
Cash Capitalized Website Development & Internal-Use Software($M)
6.106.306.504.504.104.203.702.402.502.803.402.60
Finished Goods Inventory($M)1
70.75843.92758.997.127.135.128.126.61815.2
Pharmaceutical Raw Materials, APIs & Packaging Inventory($M)
37.129.735.253.247.144.74929.3211411.87.20
Manufacturer's Discount & Rebate Receivables (Branded GLP-1 Partnerships)($M)2
345347132
Prepaid Vendor & Pharmaceutical Supply Deposits($M)
13.6125.6035.6
Accrued Marketing & Media Liabilities($M)
20.2269.3016.718.81414.421.817.812.710.712.3
Non-Cancelable Purchase Obligations — Total($M)3
62.17136.93227.326.421.22223.55.505.807.30
Purchase Obligations — Due Within Year 1($M)
20.323.711.714.813.513.210.17.108.802.802.404.80
Purchase Obligations — Due in Year 2($M)
19.819.67.9014.611.49.808.507.5070.300.102.40
Purchase Obligations — Due in Year 3($M)
11.411.45.102.500.800.800.207.205.30
Undiscounted Future Operating Lease Payments — Total($M)4
28125923221721810894.214.414.614.915.513
Undiscounted Operating Lease Payments — Next 12 Months($M)
22.622.316.912.312.39.609.302.802.702.702.702.10
Operating Lease Cost($M)
6.705.60553.603.601.300.800.800.800.600.70
Variable Lease Cost($M)
0.700.500.400.500.300.200.100.100.200.100.100.10
Operating Lease Weighted-Average Discount Rate(%)
6.0%6.1%6.0%6.1%6.1%6.3%6.8%8.7%8.8%8.9%8.9%8.9%
Convertible Senior Notes, Net Carrying Value($M)1
1,3671,365974973971970
0.00% Convertible Senior Notes Due 2030 — Principal Face Value($M)
1,0001,0001,0001,0001,0001,000
Revolving Credit Facility — Remaining Undrawn Borrowing Capacity($M)
161162162168168174
Share Repurchase Program — Remaining Authorization($M)
22522522522555.5656565705019.948
Finite-Lived Acquired Intangible Assets, Gross($M)3
48748830823122056.559.757.657.6292929
Finite-Lived Acquired Intangible Assets, Net($M)
39742326119619540.743.443.444.817.117.918.6
Amortization of Acquired Intangible Assets($M)
27.318.712.59.609.202.802.101.400.900.800.700.70
Estimated Intangible Amortization — Next 12 Months($M)
97.79736.44136.4885.505.502.602.602.80
Revenue($M)2
890753608618599545586481402316278247
Cost of Revenue($M)
38127221117315712915511283.75949.142.6
Gross Profit($M)
509481397444442416431370318257229204
Total Operating Expenses($M)3
575578475435430390373351296246219205
General and Administrative Expense($M)
15216511076.280.767.348.64844.640.634.632.3
Operating Income (Loss)($M)
-66.1-97.2-78.39.2011.826.757.918.622.4119.90-0.40
Net Income (Loss)($M)
-33-86.3-92.120.615.842.549.52675.613.311.11.20
Net Cash Provided by Operating Activities($M)6
65.4-35.989.461.3149-19.110986.485.353.625.822
Total Capital Expenditures (PP&E, Intangibles & Software)($M)
39.432.336.363.969.350.45926.95.90614
Cash Paid for Acquisitions, Net of Cash Acquired($M)
-018013823.5117-05.10-015.4-0-0-0
Net Cash Used in Investing Activities($M)
-55.484.5-15.4-83.7-887-21.1-32.8-17.2-10.4-4.501320.7
Net Cash Provided by (Used in) Financing Activities($M)
-18.9342-77.9-97.5-39889-23-13.7-38.8-25.1-30.3-4
Depreciation and Amortization($M)
38.229.52218.117.710.58.306.104.403.6032.70
Total Stock-Based Compensation Expense($M)
64.542.136.934.540.235.724.924.324.9241917.8
Total Assets($M)7
3,5473,6292,2672,1552,2331,878892708602481448441
Cash and Cash Equivalents($M)
6066102222293461,12527422116612910596.7
Short-Term Investments($M)
1072315293492842048.979.788.69898.4124
Accounts Receivable, Net($M)
42837515032.1
Inventories($M)
10887.879.180.110614276.164.449.140.629.822.5
Goodwill($M)
1,1111,102343278259118118113113111111111
Intangible Assets, Net($M)
39742326119619540.743.443.444.817.117.918.6
Operating Lease Right-of-Use Assets($M)
17716614413713971.762.210.910.91111.49.60
Total Liabilities($M)3
3,1923,3051,8211,6141,6521,31534223116211910497.2
Deferred Revenue (Unearned Subscription Revenue)($M)
14414116512711998.411175.332.22113.77.70
Operating Lease Liabilities (Noncurrent)($M)
19318115814814774.963.411.311.411.511.89.90
Total Stockholders' Equity($M)
355324446541581563549477440362345344

1 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar & M&A perimeter: Hims & Hers Health, Inc. (NYSE: HIMS) operates on a calendar fiscal year ending December 31 (latest reported period: Q3 2026 ended September 30, 2026). Consolidated operational metrics include ZAVA (Health Bridge Limited, operating across the UK, Germany, France, and Ireland) from its July 2025 acquisition date and Eucalyptus (operating across Australia, the UK, Germany, Japan, and Canada) from its June 2026 acquisition date.
  • KPI regime transitions: Hims & Hers retired 'Subscriptions' after Q4 2022 in favor of customer-level 'Subscribers'; retired 'Net Orders' and 'Average Order Value (AOV)' after Q4 2024 as subscribers shifted to multi-month personalized billing cadences; and retired 'Online Revenue', 'Wholesale Revenue', and 'Monthly Online Revenue per Average Subscriber' after Q4 2025 in favor of consolidated 'Monthly Revenue per Average Subscriber' ($105 in Q3 2026) and U.S. vs. Rest of the World geographic disaggregation. All retired metrics are preserved up to their respective final reported periods with explicit legacy labels.
  • Affiliated Medical Group VIEs & 503A/503B pharmacy infrastructure: Under U.S. corporate practice of medicine laws, Hims & Hers consolidates physician-owned Affiliated Medical Group and pharmacy Variable Interest Entities (VIEs) encompassing 1,586 U.S. licensed medical providers as of year-end 2025. Assets not yet placed in service reached $238.9M at Q3 2026 (>50% of gross PP&E), reflecting ongoing sterile injectable, 503A/503B compounding, lab diagnostics, and peptide manufacturing buildouts.
  • UK & European subsidiary statutory filings: Standalone audited financial statements for Hims & Hers UK Limited (Company No. 11602781, through FY2025 filed November 13, 2026) and Health Bridge Limited / ZAVA (Company No. 07392646, through FY2024 filed October 13, 2026) are prepared in British Pounds (£ millions) under UK FRS 102 and reflect statutory legal-entity performance including pre-acquisition ZAVA history.
  • Derived period-split methodology: Only cumulative-to-standalone quarterly splits from identical-scope SEC filings are computed ('Q4 = full year (10-K) − nine months (10-Q)' and 'quarter = year-to-date − previous year-to-date (cash flow statement)'). No standalone parent-only financial statements exist under U.S. GAAP.

Không hiện vì thiếu các kỳ gần đây (11)

  • Geographic Revenue Levels (United States vs. Rest of the World Revenue in $M) — already rendered natively in the Core Geographic / Segment panel; only disclosed year-over-year percentage growth rates are retained here to avoid duplication.
  • Convertible Senior Notes Due 2032 Principal Face Value ($402.5M) — issued in Q2 2026 with only 2 quarterly balance-sheet observations (Q2 2026 and Q3 2026), below the 3-consecutive-quarter minimum.
  • Accounts Receivable Derecognized Under Receivable Purchase Facility ($434.5M in Q3 2026) — facility established in Q2 2026 with derecognized volume disclosed for fewer than 3 consecutive quarters.
  • Eucalyptus Standalone Post-Acquisition Revenue Contribution (~$40M in Q2 2026 and ~$135M in Q3 2026) — acquired in June 2026 with only 2 quarterly management callouts to date, below the 3-quarter minimum.
  • 2025 Comparative Quarters for Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net Income (Q1–Q3 2025) — Hims & Hers introduced these Non-GAAP measures in Q1 2026 without recast Q4 2025 figures; historical comparative cells prior to Q1 2026 are omitted to preserve gap-free quarterly contiguity.
  • 2020 Observation in Q1 2025 Slide Deck Peer Market Share Chart — Hims & Hers swapped the 'Share of Observed Total Sales' and 'Share of Observed Total Customers' chart titles in its Q1 2025 deck before correcting them in 2026 decks; peer share series use the authoritative 2021–2025 series from the Q3 2026 Investor Presentation.
  • Active Clinical Specialties Count by Year (Sexual Health, Dermatology, Mental Health, Weight Loss, Hormone Health, Labs) — presented as qualitative text lists on Investor Presentation slides rather than numeric counts.
  • Facility Square Footage & Cumulative Multi-Year Medical Consultations — disclosed exclusively as inequality bounds ('more than 700,000 sq. ft.', 'over 1 million sq. ft.', 'more than 20 million consultations') rather than exact point values.
  • Customer Retention Rate & Payback Period Months — disclosed qualitatively as '<1 year payback period' or single-cohort illustrative cumulative online gross profit curves (Q1 2025 cohort) rather than a recurring company-wide time series.
  • Forward Guidance & Long-Term 2030 Targets (Q4 2026 outlook, updated FY2026 outlook, and 2030 ambition of >=$6.5B revenue / >=$1.3B Adjusted EBITDA) — forward-looking targets for unreported periods are excluded from historical actual series.
  • Standalone Environmental / Scope 1–3 GHG Emissions Report — Hims & Hers has not published a standalone quantitative ESG / GHG inventory report through November 2026.

Dữ liệu cập nhật 2026-11-14.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Hims & Hers Health

See a number that looks wrong?